Free Access
Med Sci (Paris)
Volume 29, Number 12, Décembre 2013
Page(s) 1105 - 1110
Section M/S Revues
Published online 20 December 2013
  1. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009 ; 72 : 1976–1983. [CrossRef] [PubMed] [Google Scholar]
  2. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002 ; 360 : 2018–2025. [CrossRef] [PubMed] [Google Scholar]
  3. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997 ; 62 : 112–118. [CrossRef] [PubMed] [Google Scholar]
  4. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997 ; 244 : 153–159. [CrossRef] [PubMed] [Google Scholar]
  5. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354 : 899–910. [CrossRef] [PubMed] [Google Scholar]
  6. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010 ; 362 : 387–401. [CrossRef] [PubMed] [Google Scholar]
  7. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011 ; 365 : 1293–1303. [CrossRef] [PubMed] [Google Scholar]
  8. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012 ; 367 : 1098–1107. [CrossRef] [PubMed] [Google Scholar]
  9. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012 ; 366 : 1000–1009. [CrossRef] [PubMed] [Google Scholar]
  10. Papeix C, Lubetzki C. Anticorps monoclonaux dans la sclérose en plaques. Med Sci (Paris) 2009 ; 25 : 1113–1115. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  11. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012 ; 380 : 1819–1828. [CrossRef] [PubMed] [Google Scholar]
  12. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011 ; 378 : 1779–1787. [CrossRef] [PubMed] [Google Scholar]
  13. Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 2012 ; 167 : 1035–1047. [CrossRef] [PubMed] [Google Scholar]
  14. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993 ; 259 : 1321–1324. [CrossRef] [PubMed] [Google Scholar]
  15. Van der Aa A, Hellings N, Medaer R, et al. T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin Exp Immunol 2003 ; 131 : 155–168. [PubMed] [Google Scholar]
  16. Mannie MD, Blanchfield JL, Islam SM, Abbott DJ., Cytokine-neuroantigenfusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis. Front Immunol 2012 ; 3 : 255. [CrossRef] [PubMed] [Google Scholar]
  17. Kaushansky N, Kerlero de Rosbo N, Zilkha-Falb R, et al. Multi-epitope-targeted immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides. PLoS One 2011 ; 6 : e27860. [CrossRef] [PubMed] [Google Scholar]
  18. Billetta R, Ghahramani N, Morrow O, et al. Epitope-specific immune tolerization ameliorates experimental autoimmune encephalomyelitis. Clin Immunol 2012 ; 145 : 94–101. [CrossRef] [PubMed] [Google Scholar]
  19. Perron H, Garson JA, Bedin F, et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The collaborative research group on multiple sclerosis. Proc Natl Acad Sci USA 1997 ; 94 : 7583–7588. [CrossRef] [Google Scholar]
  20. Curtin F, Lang AB, Perron H, et al. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther 2012 ; 34 : 2268–2278. [CrossRef] [PubMed] [Google Scholar]
  21. Lubetzki C. Sclérose en plaques : quelles possibilités de régénération ? Bull Acad Natl Med 2008 ; 192 : 495–506. [PubMed] [Google Scholar]
  22. Lubetzki C, Williams A, Stankoff B. Promoting repair in multiple sclerosis: problems and prospects. Curr Opin Neurol 2005 ; 18 : 237–244. [CrossRef] [PubMed] [Google Scholar]
  23. Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009 ; 65 : 304–315. [CrossRef] [PubMed] [Google Scholar]
  24. Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008 ; 29 : 558–565. [CrossRef] [PubMed] [Google Scholar]
  25. Papeix C, Lubetzki C. Anticorps monoclonaux dans la sclérose en plaques. Med Sci (Paris) 2009 ; 25 : 1113–1115. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  26. Cuvillier O. Les récepteurs de la sphingosine 1-phosphate. Med Sci (Paris) 2012 ; 28 : 951–957. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  27. Sibilia J. Protéine de fusion ou anticorps monoclonal. Med Sci (Paris) 2009 ; 25 : 1033–1038. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.